GlaxoSmithKline Abreva $10 Mil. Sales Help Offset Smoking Cessation Woes
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline's Abreva posted $10 mil. in sales during the OTC cold sore medication's first full quarter on the U.S. market.